Regulus Therap (RGLS) Misses Q2 EPS by 10c

Regulus Therap (NASDAQ: RGLS) reported Q2 EPS of ($0.29), $0.10 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $3.19 million.

For earnings history and earnings-related data on Regulus Therap (RGLS) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M
• Ally Financial schedules release of third quarter 2026 financial results